Skip to main content
. 2013 Jul 31;28(8):1134–1138. doi: 10.3346/jkms.2013.28.8.1134

Table 3.

Radiographic progression between patients who took tofacitinib and those who took conventional DMARDs for 1 and half year. SENS score change during the interval was compared between the groups

graphic file with name jkms-28-1134-i003.jpg

*Patients who were randomized to tofacitinib in the phase IIb study were included. Patients who were randomized to placebo or adalimumab were excluded. Mann-Whitney test. DMARD, disease modifying anti-rheumatic drug; SD, standard deviation.